What should myeloma patients know about bispecific antibodies? скачать в хорошем качестве

What should myeloma patients know about bispecific antibodies?

In this week's #askdrdurie myeloma expert Dr. Brian G.M. Durie discusses what patients should know about bispecific antibodies. The BOTTOM LINE: Bispecific antibodies are new upcoming therapies for myeloma patients. There are many types of bispecific antibodies currently in clinical trials. They are expected to be approved for use in myeloma in the near future. _______________ Improving Lives | Finding the Cure Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy. Subscribe to our channel:    / imfmyeloma   Visit our website at: https://www.myeloma.org Find us online: Facebook: @myeloma |   / myeloma   Twitter: @IMFMyeloma |   / imfmyeloma   Instagram: @imfmyeloma |   / imfmyeloma   LinkedIn:   / international-myeloma-foundation   Support the IMF! http://bit.ly/WskQHC Category Nonprofits & Activism License Standard YouTube License In most cases, captions are autogenerated by YouTube.